257 Diagnostic utility of molecular and imaging biomarkers 2 malignant histology, ni included indeterminate cytology other inclusion and exclusion criteria modality PTC FVPTC FTC FTC-OV MTC other n.s. follicular or Hürthle cell proliferation suspicious TN; hypoechoic on US or cold on scintigraphy; scheduled for surgery; no autonomous goiter PET 5 3 2 microfollicular pattern TN; scheduled for surgery; no PET for recurrent disease PET/CT 1 inconclusive palpable solitary TN; scheduled for hemithyroidectomy; no DM; not pregnant PET 2 3 1 follicular neoplasm TN >1cm PET 2 11 2 hypercellular follicular, oxyphilic or suspicious TN; scheduled for (hemi) thyroidectomy; normal TSH; no uncontrolled DM; no other malignancy; not pregnant; no incidental mPTC PET 4 4 2 1 follicular or Hürthle cell neoplasm TN; able to undergo surgery; not pregnant or breastfeeding, body weight <400lb/181kg PET/CT 3 3 1 follicular neoplasm TN; scheduled for surgery PET 1 4 indeterminate adult with solitary or dominant TN; palpable or ≥1cm on US; euthyroid; scheduled for surgery; no history of neck surgery or radiotherapy PET/CT (n=49) or PET (n=2) 2 5 1 1 1 Bethesda III or IV (ni=29) or indeterminate follicular lesion (ni=27) adult with TN ≥1cm; normal TSH; no DM PET/CT 7 3 12 Bethesda IV TN; normal TSH; no autonomous TN; no uncontrolled DM; not pregnant or breastfeeding; FNAC possible (no coagulopathy or technical impossibility) PET/CT 8 1 3 1 TIR3 TN >1cm; scheduled for surgery; euthyroid, undetectable thyroperoxidase and Tg autoantibodies partial body PET/CT 13 5 321627 6 2 17 0
RkJQdWJsaXNoZXIy MTk4NDMw